Trinity Biotech Secures Continued U.S. Government Funding for HIV Testing

Trinity Biotech ( (TRIB) ) has issued an announcement.

Trinity Biotech announced a positive update regarding the U.S. government’s funding for HIV testing programs using their rapid HIV tests. On February 1, 2025, the U.S. Department of State confirmed a waiver that ensures continued funding under the President’s Emergency Plan for AIDS Relief, allowing the company to maintain its operations in this critical area.

More about Trinity Biotech

Trinity Biotech is a commercial-stage biotechnology firm based in Ireland, focusing on human diagnostics and diabetes management solutions, including wearable biosensors.

YTD Price Performance: -5.16%

Average Trading Volume: 2,223,627

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $10.23M

For detailed information about TRIB stock, go to TipRanks’ Stock Analysis page.